NCT05467709

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Concert Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This is a single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to determine the effect of CTP-543 on the pharmacokinetics (PK) of midazolam in healthy adult subjects

Conditions

• Health Volunteers

Interventions

Type	Name	Description
DRUG	Midazolam	2 mg Day 1 and Day 16
DRUG	CTP-543	12 mg q12 hour for 14 consecutive days starting on Day 3

Timeline

• Start date: 2022-06-21
• Primary completion: 2022-06-30
• Completion: 2022-07-07
• First posted: 2022-07-20
• Last updated: 2022-07-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study